MetaVia’s DA-1726 Stuns with 6.3% Weight Loss in Phase 1

April 15, 2025

DENVER, Colo., Apr 15, 2025 (247marketnews.com)- MetaVia (NASDAQ:MTVA) unveiled Phase 1 MAD trial results for DA-1726, its novel 3:1 ratio GLP-1/glucagon dual receptor agonist aimed at obliterating obesity. This 4-week trial slashed up to 6.3% body weight and 3.9 inches off waists, signaling a potential best-in-class contender in an estimated $100 billion obesity drug market.

DA-1726, a once-weekly injectable oxyntomodulin (OXM) analog, wowed in the 28-day, 36-subject trial (NCT 06252220), hitting a mean 4.3% weight loss at the 32 mg dose by Day 26 (p=0.0005), with no titration needed.

Hyung Heon Kim, MetaVia’s President and CEO, stated, “The Phase 1 MAD data underscore DA-1726’s potential as a best-in-class obesity drug demonstrating compelling safety, tolerability and strong weight loss effects. The data also indicates strong clinical characteristics, with compelling tolerability and a maximum weight loss of -6.3% at the 32 mg dose, which is not yet the maximum tolerated dose, along with a mean weight reduction of -4.3% from baseline. Although subjects in this study were exposed to study drug or placebo for a total of 26 days, no signs of plateau were observed. Given GLP-1R lowers glucose levels while GCGR increases them, the 3:1 ratio of DA-1726 may provide an optimal balance to achieve a sustainable and tolerable therapeutic effect in this class of drugs. Additionally, early satiety was observed in 83% (5 of 6) of patients on the 32 mg dose, which we believe may be suggestive of efficacy and we anticipate that greater weight loss may be seen in longer duration studies. With the mean baseline of 41 inches, DA-1726 showed a waist circumference reduction of 1.6 inches on average, with a maximum reduction of 3.9 inches by day 33, which we believe is a result of GCGR breaking down the white adipose tissue, as was reported in the preclinical poster we presented at EASL 2024. It is important to note that the mean waist circumference reductions were somewhat sustained with a 1.46 inch reduction almost a month after the last dosing. Further, DA-1726 demonstrated potentially best-in-class lowering of fasted glucose of -5.3 mg/dL and a maximum of -18 mg/dL at Day 26, allowing for a potential expansion into Type 2 Diabetes and obese MASH patients. Unlike amylin which reduces appetite, or GIP which controls AEs, glucagon has its own therapeutic target other than weight loss, mainly in the liver. DA-1726 shows strong signals that may benefit obese patients with at least one comorbidity, as per FDA guidance. Not all obese patients need to lose 30% of their weight and it is our goal to develop an obesity drug that can be used safely in all obese patients with different comorbidities.

Stellar Glucose control, -18 mg/dL max, -5.3 mg/dL mean fasted glucose drop.

Waistlines shrank a mean 1.6 inches, max 3.9 inches, flashing glucagon receptor (GCGR) muscle.

No serious adverse events, only mild GI issues (25% of subjects, mostly gone in 24 hours), with 12.5% nausea and 16.7% vomiting versus placebo’s 8.3%.

Kim further said, “It is well known that many patients on current GLP-1 agonists discontinue treatment due to tolerability issues, with 20% to 30% stopping within the first month and up to 70% within a year. With DA-1726’s balanced activation of GLP1R and glucagon receptors enhancing energy expenditure, we remain confident in its potential to become a best-in-class obesity drug, with the further potential to offer superior tolerability than currently marketed GLP-1 agonists and those in late-stage clinical trials. Based on these results, we are currently planning to conduct a Phase 1 Part 3 study which will investigate DA-1726 on Wegovy® early drop-out patients. Our goal is to generate data showing the superiority of DA-1726 with respect to tolerability and safety, along with weight loss and other secondary endpoints. In parallel, based on the drug’s clean safety profile, one or more additional cohorts with a higher dose will be added to the Phase 1 study in order to further explore the maximum tolerated dose, which will allow us to realize the full potential of DA-1726.”

The trial’s just the start, MetaVia’s adding cohorts to nail the max dose and planning Phase 1 Part 3 to pit DA-1726 against Wegovy dropouts, eyeing superiority in safety, weight loss, and more. Preclinical data already outshines semaglutide, tirzepatide, and survodutide, with better weight loss, lean mass preservation, and lipid control.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (MTVA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.